Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

DarioHealth (DRIO) EBIT (2016 - 2025)

DarioHealth filings provide 13 years of EBIT readings, the most recent being -$8.6 million for Q4 2025.

  • On a quarterly basis, EBIT rose 26.62% to -$8.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$36.7 million, a 36.52% increase, with the full-year FY2025 number at -$36.7 million, up 36.52% from a year prior.
  • EBIT hit -$8.6 million in Q4 2025 for DarioHealth, up from -$9.5 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$8.6 million in Q4 2025 to a low of -$22.5 million in Q3 2021.
  • Median EBIT over the past 5 years was -$14.3 million (2021), compared with a mean of -$14.2 million.
  • Biggest five-year swings in EBIT: tumbled 336.65% in 2021 and later surged 58.41% in 2022.
  • DarioHealth's EBIT stood at -$21.7 million in 2021, then surged by 58.41% to -$9.0 million in 2022, then crashed by 57.77% to -$14.2 million in 2023, then increased by 17.92% to -$11.7 million in 2024, then rose by 26.62% to -$8.6 million in 2025.
  • The last three reported values for EBIT were -$8.6 million (Q4 2025), -$9.5 million (Q3 2025), and -$9.2 million (Q2 2025) per Business Quant data.